The Use of an Adjuvant System Improves Innate and Adaptive Immune Response When Associated with a () Antigen in a Vaccine Candidate against () Infection.

Background: The adjuvants' optimal dose and the administration route can directly influence the epitope recognition patterns and profiles of innate response. We aimed to establish the effect and the optimal dose of adjuvant systems for proposing a vaccine candidate to be employed with () .

Methods: We evaluated the adjuvants saponin (SAP), monophosphoryl lipid A (MPL) and resiquimod (R-848) isolated and combined as adjuvant systems in a lower dose corresponding to 25%, 33%, and 50% of each adjuvant total dose. Male outbred BALB/c mice were divided into 13 groups, SAP, MPL, and R-848 isolated, and the adjuvant systems SAP plus MPL (SM), SAP plus R-848 (SR), and MPL plus R-848 (MR).

Results: SM50 increased levels of all chemokines analyzed and TNF production, while it presented an increased inflammatory cell infiltrate in the skin with macrophage recruitment. Thus, we proposed a vaccine candidate employing () antigen associated with the SM adjuvant system against experimental () challenge. We observed a significant increase in the frequency of cells expressing the central and effector memory CD4 T cells phenotype in immunized mice with the LBSM50. In the liver, there was a decreased parasite load when mice received LBSM50.

Conclusions: When combined with () antigen, SM50 increases TNF and IFN-γ, which generates central and effector memory CD4 T cells. Therefore, using an adjuvant system can promote an effective innate immune response with the potential to compose future vaccines.